also of historical interest only is that the phase 3 trial that ultimately led to approval of scenesse also failed to demonstrate a significant difference in pain free sun exposure.
hopefully the bar is higher with the fda now that epp has an accepted standard of care, even if only a few hundred patients are accessing treatment in the US.
EPP Monomply News, page-6
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.16 |
Change
0.090(0.60%) |
Mkt cap ! $759.1M | |||
| Open | High | Low | Value | Volume |
| $15.12 | $15.44 | $15.02 | $1.063M | 70.10K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 126 | $15.14 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.27 | 764 | 3 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| CUV (ASX) Chart |